Bretylium opens mucosal amiloride-sensitive sodium channels.
Addition of the quanternary ammonium compound, bretylium, to the outer surface of a frog skin leads to an increase in the potential difference and in the short circuit current across the skin. Bretylium does not have any effect when applied to the inside face of the frog skin. The effect of bretylium is dependent upon the presence of sodium ions in the outer medium; it is depressed when sodium is replaced by choline or potassium but not when lithium substitutes for sodium. The bretylium effect is blocked by the specific sodium channel blocker, amiloride. It is proposed that bretylium opens mucosal, amiloride-sensitive sodium channels.
D000584:Amiloride / Q000494:pharmacology*; D000818:Animals; D001949:Bretylium Compounds / Q000494:pharmacology*; D001950:Bretylium Tosylate / Q000494:pharmacology*; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism*; D008564:Membrane Potentials / Q000187:drug effects; D009092:Mucous Membrane / Q000187:drug effects / Q000378:metabolism; D011719:Pyrazines / Q000494:pharmacology*; D011894:Rana pipiens; D012867:Skin / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism*
D001949:Bretylium Compounds; D007473:Ion Channels; D011719:Pyrazines; D001950:Bretylium Tosylate; D000584:Amiloride; D012964:Sodium